The UPV/EHU’s COMPMECH research group has patented a mechatronic instrument that uses a mobile platform to stimulate the patient's balance in a controlled manner and measures his/her response. This prototype, which enables rehabilitation work to be systematized while monitoring the patient's evolution over time, is the result of close collaboration with professionals from different departments at Gorliz Hospital.

A recent study at Earth-Life Science Institute (ELSI) at Institute of Science Tokyo has developed a theoretical model that uncovers the dual role of polyploidy—organisms carrying extra genome copies—in evolution. Their findings reveal that polyploidy can stabilise populations in predictable environments, where the evolution of novel traits is not required, enabling organisms to adapt and thrive in challenging conditions by accelerating evolutionary innovation. This breakthrough offers fresh insights into evolutionary mechanisms and their implications for microbiology, biotechnology, and medicine.

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free survival (PFS) rate of olaparib maintenance therapy in this specific patient group, offering insights into its potential as a therapeutic option.